ATXS Astria Therapeutics Inc
11,386
$9.71
$0.02
(0.21%)
| Watchers | 11,386 |
| 52-Wk Low | $4.26 |
| 52-Wk High | $16.90 |
| Market Cap | $533.21M |
| Volume | 561,758.00 |
| 52-Wk High | $16.90 |
| 52-Wk Low | $4.26 |
Astria Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate UpdateBusiness Wire • 5 days ago
Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today reported financial results for the...
Share to Feed
Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced that it will present...
Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, granted stock options to purchase 173,500...
Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced the appointment of Sunil...
Related Stocks: ATXS...
Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, granted stock options to purchase 9,000...
Over the last three days, A.I.dvisor has detected that ATXS's AroonUp green line (see chart) is above 70, while the AroonDown red line is below 30. When the green line goes above 70 while the red...
This price move could indicate a change in the trend, and may be a sell signal for investors...
Astria Therapeutics, Inc. (NASDAQ:ATXS - Get Free Report) was the target of a significant growth in short interest during the month of March. As of March 15th, there was short interest totalling...
Wedbush reiterated their outperform rating on shares of Astria Therapeutics (NASDAQ:ATXS Free Report) in a research report released on Tuesday, Benzinga reports. The brokerage currently has...